Evropska unija - slovenščina - EMA (European Medicines Agency)

laboratorios hipra, s.a. - mycoplasma hyopneumoniae, strain 7304 (nexhyon), expressing the capsid protein of porcine circovirus type 2a, inactivated - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - prašiči - for the active immunisation of pigs:to reduce lung lesions associated with porcine enzootic pneumonia caused by mycoplasma hyopneumoniae. also, to reduce the incidence of these lesions (as observed in field studies). to reduce viraemia, virus load in lungs and lymphoid tissues and the duration of the viraemic period associated with diseases caused by porcine circovirus type 2 (pcv2). efficacy against pcv2 genotypes a, b and d has been demonstrated in field studies. to reduce culling rate and the loss of daily weight gain caused by mycoplasma hyopneumoniae and/or pcv2 related diseases (as observed at 6 months of age in field studies). mycoplasma hyopneumoniae: onset of immunity: 3 weeks after vaccinationduration of immunity: 23 weeks after vaccinationporcine circovirus type 2:onset of immunity: 2 weeks after vaccinationduration of immunity: 22 weeks after vaccinationin addition, a reduction in nasal and faecal shedding and the duration of nasal excretion of pcv2 was demonstrated in animals challenged at 4 weeks and at 22 weeks after vaccination.

Evropska unija - slovenščina - EMA (European Medicines Agency)

zoetis belgium sa - inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2 orf2 protein, inactivated mycoplasma hyopneumoniae, strain p-5722-3 - inaktivirano virusne in inaktivirano bakterijskih cepiv - prašiči - za aktivno imunizacijo prašičev od 3 tednov starosti proti prašičji circovirus tipa 2 (pcv2) za zmanjšanje virusne obremenitve) v krvi in lymphoid tkiv in odpade odpuščanje, ki jih povzroča okužba z pcv2. za aktivno imunizacijo prašičev v starosti 3 tednov pred mikroplazma hyopneumoniae za zmanjšanje pljučne poškodb, ki jih povzročajo okužbe z m. hyopneumoniae.

Evropska unija - slovenščina - EMA (European Medicines Agency)

intervet international b.v. - prašičev circovirus tipa 2 (pcv2) orf2 podenote antigen, mikroplazma hyopneumoniae j sev inaktivirano - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - prašičev (za pitanje) - za aktivno imunizacijo prašičev za zmanjšanje viraemia, virus nalagajo v pljučih in lymphoid tkiv, virus prelivanje zaradi prašičev circovirus tipa 2 (pcv2) okužbe, in resnosti pljuč poškodb, ki jih povzročajo mikroplazma hyopneumoniae okužbe. da bi zmanjšali izgubo dnevnega povečanja telesne mase med končnim obdobjem ob okužbah z mycoplasmo hyopneumoniae in / ali pcv2 (kot je bilo ugotovljeno v terenskih študijah).

Evropska unija - slovenščina - EMA (European Medicines Agency)

zoetis belgium - inactivated mycoplasma hyopneumoniae, strain p-5722-3, inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2a open reading frame 2 (orf2) protein, inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2b orf2 protein - imunologija za suidae - prašičev (za pitanje) - active immunisation of pigs against porcine circovirus type 2 to reduce viral load in blood and lymphoid tissues, fecal shedding and the lesions in lymphoid tissues associated with pcv2 infection. protection was demonstrated against porcine circovirus types 2a, 2b and 2d. active immunisation of pigs against mycoplasma hyopneumoniae to reduce the lung lesions associated with mycoplasma hyopneumoniae infection.  onset of immunity (both vaccination schedules): 3 weeks after (the last) vaccination.  duration of immunity (both vaccination schedules): 23 weeks after (the last) vaccination.  in addition, vaccination has been shown to reduce body weight gain losses under field conditions.

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

boehringer ingelheim vetmedica gmbh 55216 ingelheim/rhein nemČija 2 -

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

gsk d.o.o., ljubljana - virus hepatitisa a, inaktivirani - suspenzija za injiciranje - virus hepatitisa a, inaktivirani 720 elisa enot / 0,5 ml - cepivo proti hepatitisu tipa a s celimi virusi, inaktivirano

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

gsk d.o.o., ljubljana - virus hepatitisa a, inaktivirani - suspenzija za injiciranje - virus hepatitisa a, inaktivirani 1440 elisa enot / 1 ml - cepivo proti hepatitisu tipa a s celimi virusi, inaktivirano

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

gsk vaccines gmbh - virus klopnega meningoencefalitisa, inaktivirani - suspenzija za injiciranje - virus klopnega meningoencefalitisa, inaktivirani 3 µg / 1 ml - cepivo proti klopnemu meningoencefalitisu, s celimi virusi, inaktivirano

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

gsk vaccines gmbh - virus klopnega meningoencefalitisa, inaktivirani - suspenzija za injiciranje - virus klopnega meningoencefalitisa, inaktivirani 3 µg / 1 ml - cepivo proti klopnemu meningoencefalitisu, s celimi virusi, inaktivirano

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

gsk vaccines gmbh - virus klopnega meningoencefalitisa, inaktivirani - suspenzija za injiciranje - virus klopnega meningoencefalitisa, inaktivirani 0,75 µg / 0,25 ml - cepivo proti klopnemu meningoencefalitisu, s celimi virusi, inaktivirano